| Formulary Chapter 5: Infections - Full Chapter
|
| 05.03.01 |
HIV infection |
|
|
 |
Note: The classification ‘hospital use only’ does not prevent supply of medicines by Primary Care, e.g. use of hospital-based prescription (HBP) stationery. |
|
Abacavir
|
Formulary
 
|
 Risk Minimisation Materials
|
 Risk Minimisation Materials
 Risk Minimisation Materials: Patient Alert Card
Drug Safety Update: Abacavir: risk of myocardial infarction - update from epidemiological studies (July 2009)
SMC 174/05: Abacavir for the treatment of HIV-1 infection in adults and adolescents (May 2005)
|
Abacavir/lamivudine
|
Formulary
|
Risk Minimisation Materials
|
Risk Minimisation Materials
Risk Minimisation Materials: Patient Alert Card
Drug Safety Update: Abacavir: risk of myocardial infarction—update from epidemiological studies (July 2009)
|
Atazanavir
|
Formulary
|
|
SMC 656/10: Atazanavir for the treatment of paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (Dec 2010)
SMC 520/08: Atazanavir for antiretroviral treatment naïve HIV-1 infected adults (Dec 2008)
SMC 120/04: Atazanavir for the treatment of HIV-1 infected, antiretroviral treatment experienced adults (Sept 2004)
|
bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)
(50mg/200mg/25mg film-coated tablets)
|
Formulary
|
|
SMC 2093: Biktarvy® for the treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir (Sept. 2018).
|
Darunavir
|
Formulary
|
|
Drug Safety Update Articles: Darunavir
SMC advice directory: Darunavir for the treatment of HIV-1 infection
|
Darunavir/cobicistat
(Rezolsta®)
|
Formulary
|
|
Drug Safety Update: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (July 2018)
Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
SmPC: darunavir/cobicistat
SMC 1081/15: Darunavir/cobicistat for the treatment of HIV-1 infection in adults aged 18 years or older (Aug 2015).
|
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide
(Symtuza®)
|
Formulary
|
|
SmPC: darunavir/cobicistat/emtricitabine/tenofovir alafenamide
Drug Safety Update: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (July 2018)
SMC 1290/18: Symtuza® for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg) (Jan 2018)
|
Dolutegravir
|
Formulary
|
|
Drug Safety Update Articles: Dolutegravir
SMC 1253/17: Dolutegravir for the treatment of HIV-1 infected children aged >6 to 12 years of age (July 2017)
SMC 961/14: Dolutegravir for the treatment of HIV-1 infected adults and adolescents above 12 years of age (May 2014)
|
Dolutegravir/abacavir/lamivudine
(Triumeq®)
|
Formulary
|
Risk Minimisation Materials
|
Risk Minimisation Materials
SmPC: dolutegravir/abacavir/lamivudine
Drug Safety Update Articles: Triumeq
SMC 1009/14: Dolutegravir/abacavir/lamivudine for the treatment of HIV infected adults and adolescents above 12 years of age weighing at least 40 kg (Dec 2014).
|
Dolutegravir/lamivudine
(Dovato®)
|
Formulary
|
|
SmPC: dolutegravir/lamivudine
SMC 2205: Dolutegravir/lamivudine for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine (Sept 2019)
|
dolutegravir/rilvipirine (Juluca®)
(50mg/25mg film-coated tablets)
|
Formulary
|
|
SmPC: dolutegravir/rilvipirine
SMC 2091: Juluca® for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months no history of virological failure and no resistance to NNRTI or integrase inhibitor (Sept 2018)
|
Efavirenz
|
Formulary
|
|
SMC 1125/15: Efavirenz for the treatment of HIV-1 infected children aged 3 months to 3 years and weighing at least 3.5kg (Dec 2015)
|
Efavirenz/emtricitabine/tenofovir disoproxil
|
Formulary
|
|
SMC 442/08: Efavirenz/emtricitabine/tenofovir disoproxil for the treatment of HIV-1 infection in adults (April 2008)
|
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
(Genvoya®)
|
Formulary
|
|
SmPC: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Drug Safety Update Articles: Elvitegravir
Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
SMC 1142/16: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for the treatment of HIV-1 infection in adults and adolescents (May 2016)
|
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
(Stribild® )
|
Formulary
|
|
SmPC: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
Drug Safety Update Articles: Elvitegravir
Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
SMC 887/13: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil treatment of HIV-1 infection in adults aged 18 years and over ( Aug 2013).
|
Emtricitabine/rilpivirine/tenofovir disoproxil
(Eviplera®)
|
Formulary
|
|
SmPC: emtricitabine/rilpivirine/tenofovir disoproxil
SMC 951/14: Emtricitabine/tenofovir/rilpiverine for the treatment of HIV-1 infection in adults (April 2014)
SMC 759/12: Emtricitabine/tenofovir/rilpiverine for the treatment of HIV-1 infection in antiretroviral treatment-naive adults (Feb 2012)
|
Emtricitabine/tenofovir alafenamide
(Descovy®)
|
Formulary
|
Descovy® 200/25 film-coated tablets
(200mg emtricitabine/25mg tenofovir alafenamide)
Descovy® 200/10 film-coated tablets
(200mg emtricitabine/10mg tenofovir alafenamide)
|
SmPC: emtricitabine/tenofovir alafenamide
SMC 1169/16: Emtricitabine/tenofovir alafenamide for the treatment of HIV-1 infection in adults and adolescents (Aug 2016)
|
Emtricitabine/tenofovir disoproxil
|
Formulary
|
|
SMC 1225/17: Emtricitabine/tenofovir disoproxil in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk (April 2017)
SMC 237/06: Emtricitabine/tenofovir disoproxil for the treatment of HIV-1 infection in adults (Feb 2006)
|
Etravirine
|
Formulary
|
|
SMC 901/13: Etravirine for the treatment of HIV-1 infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age (Sept 2013)
SMC 530/09: Etravirine for the treatment of HIV-1 infection in antiretroviral treatment experienced adult patients (Aug 2009)
|
Lamivudine
(150mg, 300mg)
|
Formulary
|
|
|
|
Lamivudine/zidovudine
|
Formulary
|
|
SmPC: lamivudine/zidovudine
|
Lopinavir/ritonavir
(Kaletra®)
|
Formulary
|
Kaletra® 200/50 film-coated tablets (200mg lopinavir/50mg ritonavir)
Kaletra® 400mg/100mg/5mL oral solution (80mg lopinavir/20mg ritonavir/mL)
|
SmPC: lopinavir/ritonavir
Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
SMC 1302/18: Lopinavir/ritonavir oral solution for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to ≤2 years (Feb 2018)
SMC 326/06: Lopinavir/ritonavir for the treatment of HIV-1 infected adults and children above the age of 2 years (Nov 2006).
|
Nevirapine
|
Formulary
|
|
SMC 760/12: for the treatment of HIV-1 infected adults, adolescents, and children three years and above and able to swallow tablets (Feb 2012).
|
Raltegravir
|
Formulary
|
|
SMC advice directory: Raltegravir for the treatment of HIV-1 infection
|
Rilpiverine/emtrictabine/tenofovir alafenamide
(Odefsey®)
|
Formulary
|
|
SmPC: rilpiverine/emtrictabine/tenofovir alafenamide
SMC 1189/16: Rilpiverine/emtrictabine/tenofovir alafenamide for the treatment of HIV-1 infection in adults and adolescents (Oct 2016)
|
Rilpivirine hydrochloride
|
Formulary
|
|
SMC 1168/16: Rilpivirine for the treatment of HIV-1 infection in adolescents (Aug 2016)
SMC 758/12: Rilpivirine for the treatment of HIV-1 infection in adults (Feb 2012)
|
Ritonavir
|
Formulary
|
|
Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
|
Tenofovir disoproxil
|
Formulary
|
|
SMC 900/13: Tenofovir disoproxil for the treatment of HIV 1 infected paediatric and adolescent patients aged 6 to < 12 years (Sept 2013).
Q&A: Switching between liquid and tablet/capsule formulations – Which medicines require extra care?
|
Zidovudine
|
Formulary
|
|
|
|
Lamivudine 100mg
(HIV (off-label))
|
 Restricted
|
To be used in the management of HIV for dialysis and severely impaired renal patients.
|
|
|
|
|
| .... |
| Non Formulary Items |
Abacavir/lamivudine/zidovudine
(Trizivir®)
|
Non Formulary
|
Risk Minimisation Materials |
Risk Minimisation Materials
SmPC: abacavir/lamivudine/zidovudine
|
Atazanavir/cobicistat
(Evotaz®)
|
Non Formulary
|
|
SmPC: atazanavir/cobicistat
Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects (Dec 2016)
SMC 1098/15: Atazanavir/cobicistat for the treatment of HIV-1 infection in adults and adolescents (Nov 2015)
|
Didanosine
|
Non Formulary
|
|
|
|
Doravirine (Pifeltro ®)
|
Non Formulary
|
Doravirine (Pifeltro®) is not recommended for use within NHS Scotland as per SMC 2162. |
SmPC: doravirine (Pifeltro®) 100mg film-coated tablets
|
Doravirine/lamivudine/tenofovir disoproxil (Delstrigo®)
|
Non Formulary
|
Doravirine/lamivudine/tenofovir/disoproxil (Delstrigo®) is not recommended for use within NHS Scotland as per SMC 2163. |
SmPC: Delstrigo® 100mg/300mg/245mg film-coated tablets
|
Emtricitabine
|
Non Formulary
|
|
|
|
Fosamprenavir
|
Non Formulary
|
|
|
|
Indinavir
|
Non Formulary
|
|
Summary of Product Characteristics: Indinavir
|
Maraviroc (Celsentri®)
|
Non Formulary
|
Maraviroc (Celsentri®) is not recommended for use within NHS Scotland as per SMC 458/08 and SMC 1282/17 |
SMC 1282/17: Maraviroc for treatment-experienced adolescents and children of 2 years and older and weighing at least 10kg infected with only CCR5-tropic HIV-1 detectable (Oct 2017)
SMC 458/08: Maraviroc for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable (Oct 2008)
|
Saquinavir
|
Non Formulary
|
|
|
|
Tipranavir
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Homecare |
|
Traffic Light Status Information
|
|
|
